Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 10;14(11):101197. doi: 10.1016/j.tranon.2021.101197

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Published by Elsevier Inc.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 5 — Common 46 downregulated signature genes segregate patients by response and survival across 2 cohorts. (A) Heat map of signature genes from Pembrolizumab-treated patients. (B) Means of RES scores from nonresponder (NR) and responder (R) Pembrolizumab-treated patients. (C) Assignments of Pembrolizumab-treated patients as nonresponder (NR) and responder (R) by predictions from signature genes. (D) Survival analysis of Pembrolizumab-treated patients with mean signature RES scores above and below the median. (E) Heat map of signature genes from Nivolumab-treated patients. (F) Means of RES scores from nonresponder (NR) and responder (R) Nivolumab-treated patients. (G) Assignments of patients from Nivolumab-treated patients as nonresponder (NR) and responder (R) by predictions from signature genes. (H) Survival analysis of Nivolumab-treated patients with mean signature RES scores above and below the median. ***p < 0.001.